JOHNSON & JOHNSON (JNJ.DE) Fundamental Analysis & Valuation

FRA:JNJ • US4781601046

Current stock price

194.18 EUR
-2.36 (-1.2%)
Last:

This JNJ.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

7

1. JNJ.DE Profitability Analysis

1.1 Basic Checks

  • JNJ had positive earnings in the past year.
  • In the past year JNJ had a positive cash flow from operations.
  • JNJ had positive earnings in each of the past 5 years.
  • Each year in the past 5 years JNJ had a positive operating cash flow.
JNJ.DE Yearly Net Income VS EBIT VS OCF VS FCFJNJ.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 13.46%, JNJ belongs to the top of the industry, outperforming 89.80% of the companies in the same industry.
  • The Return On Equity of JNJ (32.87%) is better than 79.59% of its industry peers.
  • JNJ has a Return On Invested Capital of 15.05%. This is in the better half of the industry: JNJ outperforms 75.51% of its industry peers.
  • JNJ had an Average Return On Invested Capital over the past 3 years of 15.58%. This is in line with the industry average of 14.21%.
Industry RankSector Rank
ROA 13.46%
ROE 32.87%
ROIC 15.05%
ROA(3y)14.08%
ROA(5y)12.66%
ROE(3y)34.55%
ROE(5y)31.04%
ROIC(3y)15.58%
ROIC(5y)14.64%
JNJ.DE Yearly ROA, ROE, ROICJNJ.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10 20 30 40 50

1.3 Margins

  • The Profit Margin of JNJ (28.46%) is better than 93.88% of its industry peers.
  • JNJ's Profit Margin has improved in the last couple of years.
  • The Operating Margin of JNJ (28.55%) is better than 75.51% of its industry peers.
  • In the last couple of years the Operating Margin of JNJ has grown nicely.
  • The Gross Margin of JNJ (67.98%) is comparable to the rest of the industry.
  • In the last couple of years the Gross Margin of JNJ has remained more or less at the same level.
Industry RankSector Rank
OM 28.55%
PM (TTM) 28.46%
GM 67.98%
OM growth 3Y-0.34%
OM growth 5Y3.01%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.62%
GM growth 5Y0.68%
JNJ.DE Yearly Profit, Operating, Gross MarginsJNJ.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20 40 60

5

2. JNJ.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so JNJ is still creating some value.
  • Compared to 1 year ago, JNJ has about the same amount of shares outstanding.
  • The number of shares outstanding for JNJ has been reduced compared to 5 years ago.
  • The debt/assets ratio for JNJ is higher compared to a year ago.
JNJ.DE Yearly Shares OutstandingJNJ.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B 2.5B
JNJ.DE Yearly Total Debt VS Total AssetsJNJ.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50B 100B 150B

2.2 Solvency

  • JNJ has an Altman-Z score of 4.91. This indicates that JNJ is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of JNJ (4.91) is better than 75.51% of its industry peers.
  • The Debt to FCF ratio of JNJ is 2.43, which is a good value as it means it would take JNJ, 2.43 years of fcf income to pay off all of its debts.
  • With a decent Debt to FCF ratio value of 2.43, JNJ is doing good in the industry, outperforming 77.55% of the companies in the same industry.
  • A Debt/Equity ratio of 0.56 indicates that JNJ is somewhat dependend on debt financing.
  • JNJ's Debt to Equity ratio of 0.56 is in line compared to the rest of the industry. JNJ outperforms 55.10% of its industry peers.
  • Even though the debt/equity ratio score it not favorable for JNJ, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 2.43
Altman-Z 4.91
ROIC/WACC1.52
WACC9.92%
JNJ.DE Yearly LT Debt VS Equity VS FCFJNJ.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B 80B

2.3 Liquidity

  • A Current Ratio of 1.03 indicates that JNJ should not have too much problems paying its short term obligations.
  • JNJ has a worse Current ratio (1.03) than 65.31% of its industry peers.
  • JNJ has a Quick Ratio of 1.03. This is a bad value and indicates that JNJ is not financially healthy enough and could expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 0.77, JNJ is doing worse than 71.43% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 0.77
JNJ.DE Yearly Current Assets VS Current LiabilitesJNJ.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20B 40B 60B

5

3. JNJ.DE Growth Analysis

3.1 Past

  • JNJ shows a small growth in Earnings Per Share. In the last year, the EPS has grown by 6.77%.
  • JNJ shows a small growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 6.11% yearly.
  • JNJ shows a small growth in Revenue. In the last year, the Revenue has grown by 7.87%.
  • Measured over the past years, JNJ shows a small growth in Revenue. The Revenue has been growing by 2.67% on average per year.
EPS 1Y (TTM)6.77%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%-2.53%
Revenue 1Y (TTM)7.87%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.91%

3.2 Future

  • Based on estimates for the next years, JNJ will show a quite strong growth in Earnings Per Share. The EPS will grow by 9.75% on average per year.
  • JNJ is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.80% yearly.
EPS Next Y7.91%
EPS Next 2Y8.38%
EPS Next 3Y8.73%
EPS Next 5Y9.75%
Revenue Next Year7.43%
Revenue Next 2Y6.86%
Revenue Next 3Y6.73%
Revenue Next 5Y6.8%

3.3 Evolution

  • The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
JNJ.DE Yearly Revenue VS EstimatesJNJ.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 20B 40B 60B 80B 100B
JNJ.DE Yearly EPS VS EstimatesJNJ.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 5 10 15

2

4. JNJ.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 21.18, JNJ is valued on the expensive side.
  • Compared to the rest of the industry, the Price/Earnings ratio of JNJ is on the same level as its industry peers.
  • JNJ's Price/Earnings ratio indicates a valuation a bit cheaper than the S&P500 average which is at 26.54.
  • A Price/Forward Earnings ratio of 17.92 indicates a rather expensive valuation of JNJ.
  • The rest of the industry has a similar Price/Forward Earnings ratio as JNJ.
  • JNJ's Price/Forward Earnings ratio indicates a similar valuation than the S&P500 average which is at 21.68.
Industry RankSector Rank
PE 21.18
Fwd PE 17.92
JNJ.DE Price Earnings VS Forward Price EarningsJNJ.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • The rest of the industry has a similar Enterprise Value to EBITDA ratio as JNJ.
  • Based on the Price/Free Cash Flow ratio, JNJ is valued a bit more expensive than the industry average as 61.22% of the companies are valued more cheaply.
Industry RankSector Rank
P/FCF 27.79
EV/EBITDA 16.23
JNJ.DE Per share dataJNJ.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates JNJ does not grow enough to justify the current Price/Earnings ratio.
  • JNJ has a very decent profitability rating, which may justify a higher PE ratio.
PEG (NY)2.68
PEG (5Y)3.47
EPS Next 2Y8.38%
EPS Next 3Y8.73%

6

5. JNJ.DE Dividend Analysis

5.1 Amount

  • With a Yearly Dividend Yield of 2.32%, JNJ has a reasonable but not impressive dividend return.
  • JNJ's Dividend Yield is a higher than the industry average which is at 1.96.
  • JNJ's Dividend Yield is a higher than the S&P500 average which is at 1.82.
Industry RankSector Rank
Dividend Yield 2.32%

5.2 History

  • The dividend of JNJ is nicely growing with an annual growth rate of 7.68%!
Dividend Growth(5Y)7.68%
Div Incr Years7
Div Non Decr Years7
JNJ.DE Yearly Dividends per shareJNJ.DE Yearly Dividends per shareYearly Dividends per share 2018 2019 2020 2021 2022 2023 2024 2025 2026 1 2 3 4 5

5.3 Sustainability

  • 46.19% of the earnings are spent on dividend by JNJ. This is a bit on the high side, but may be sustainable.
  • JNJ's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP46.19%
EPS Next 2Y8.38%
EPS Next 3Y8.73%
JNJ.DE Yearly Income VS Free CF VS DividendJNJ.DE Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B
JNJ.DE Dividend Payout.JNJ.DE Dividend Payout, showing the Payout Ratio.JNJ.DE Dividend Payout.PayoutRetained Earnings

JNJ.DE Fundamentals: All Metrics, Ratios and Statistics

JOHNSON & JOHNSON

FRA:JNJ (4/29/2026, 7:00:00 PM)

194.18

-2.36 (-1.2%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Industry Strength65.84
Industry Growth15.53
Earnings (Last)04-14
Earnings (Next)07-14
Inst Owners75.61%
Inst Owner ChangeN/A
Ins Owners0.04%
Ins Owner ChangeN/A
Market Cap467.70B
Revenue(TTM)96.36B
Net Income(TTM)26.80B
Analysts76.25
Price Target208.28 (7.26%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 2.32%
Yearly Dividend4.39
Dividend Growth(5Y)7.68%
DP46.19%
Div Incr Years7
Div Non Decr Years7
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)0.21%
Min EPS beat(2)-0.13%
Max EPS beat(2)0.55%
EPS beat(4)3
Avg EPS beat(4)2.17%
Min EPS beat(4)-0.13%
Max EPS beat(4)5.96%
EPS beat(8)7
Avg EPS beat(8)2.84%
EPS beat(12)10
Avg EPS beat(12)3.23%
EPS beat(16)14
Avg EPS beat(16)3.09%
Revenue beat(2)2
Avg Revenue beat(2)0.35%
Min Revenue beat(2)0.03%
Max Revenue beat(2)0.67%
Revenue beat(4)4
Avg Revenue beat(4)1.04%
Min Revenue beat(4)0.03%
Max Revenue beat(4)2.92%
Revenue beat(8)5
Avg Revenue beat(8)0.32%
Revenue beat(12)8
Avg Revenue beat(12)-0.5%
Revenue beat(16)8
Avg Revenue beat(16)-4.44%
PT rev (1m)3.72%
PT rev (3m)13.96%
EPS NQ rev (1m)-0.22%
EPS NQ rev (3m)-0.24%
EPS NY rev (1m)0.06%
EPS NY rev (3m)0.82%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)0.39%
Revenue NY rev (1m)0.22%
Revenue NY rev (3m)0.62%
Valuation
Industry RankSector Rank
PE 21.18
Fwd PE 17.92
P/S 5.81
P/FCF 27.79
P/OCF 22.32
P/B 6.71
P/tB N/A
EV/EBITDA 16.23
EPS(TTM)9.17
EY4.72%
EPS(NY)10.84
Fwd EY5.58%
FCF(TTM)6.99
FCFY3.6%
OCF(TTM)8.7
OCFY4.48%
SpS33.41
BVpS28.92
TBVpS-6.25
PEG (NY)2.68
PEG (5Y)3.47
Graham Number77.2475 (-60.22%)
Profitability
Industry RankSector Rank
ROA 13.46%
ROE 32.87%
ROCE 18.53%
ROIC 15.05%
ROICexc 17.35%
ROICexgc 70.6%
OM 28.55%
PM (TTM) 28.46%
GM 67.98%
FCFM 20.91%
ROA(3y)14.08%
ROA(5y)12.66%
ROE(3y)34.55%
ROE(5y)31.04%
ROIC(3y)15.58%
ROIC(5y)14.64%
ROICexc(3y)18.74%
ROICexc(5y)17.83%
ROICexgc(3y)70.93%
ROICexgc(5y)71.82%
ROCE(3y)18.94%
ROCE(5y)17.92%
ROICexgc growth 3Y-2.46%
ROICexgc growth 5Y-5.65%
ROICexc growth 3Y1.88%
ROICexc growth 5Y1.69%
OM growth 3Y-0.34%
OM growth 5Y3.01%
PM growth 3Y8.26%
PM growth 5Y9.82%
GM growth 3Y-0.62%
GM growth 5Y0.68%
F-Score4
Asset Turnover0.47
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF 2.43
Debt/EBITDA 1.34
Cap/Depr 64.4%
Cap/Sales 5.13%
Interest Coverage 7
Cash Conversion 71.32%
Profit Quality 73.49%
Current Ratio 1.03
Quick Ratio 0.77
Altman-Z 4.91
F-Score4
WACC9.92%
ROIC/WACC1.52
Cap/Depr(3y)61.79%
Cap/Depr(5y)58.46%
Cap/Sales(3y)5.15%
Cap/Sales(5y)5.02%
Profit Quality(3y)88.82%
Profit Quality(5y)91.38%
High Growth Momentum
Growth
EPS 1Y (TTM)6.77%
EPS 3Y2.06%
EPS 5Y6.11%
EPS Q2Q%-2.53%
EPS Next Y7.91%
EPS Next 2Y8.38%
EPS Next 3Y8.73%
EPS Next 5Y9.75%
Revenue 1Y (TTM)7.87%
Revenue growth 3Y5.6%
Revenue growth 5Y2.67%
Sales Q2Q%9.91%
Revenue Next Year7.43%
Revenue Next 2Y6.86%
Revenue Next 3Y6.73%
Revenue Next 5Y6.8%
EBIT growth 1Y15.95%
EBIT growth 3Y5.24%
EBIT growth 5Y5.76%
EBIT Next Year23.27%
EBIT Next 3Y11.78%
EBIT Next 5Y9.67%
FCF growth 1Y-0.73%
FCF growth 3Y4.65%
FCF growth 5Y-0.49%
OCF growth 1Y1.09%
OCF growth 3Y4.99%
OCF growth 5Y0.83%

JOHNSON & JOHNSON / JNJ.DE Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for JOHNSON & JOHNSON?

ChartMill assigns a fundamental rating of 5 / 10 to JNJ.DE.


What is the valuation status of JOHNSON & JOHNSON (JNJ.DE) stock?

ChartMill assigns a valuation rating of 2 / 10 to JOHNSON & JOHNSON (JNJ.DE). This can be considered as Overvalued.


How profitable is JOHNSON & JOHNSON (JNJ.DE) stock?

JOHNSON & JOHNSON (JNJ.DE) has a profitability rating of 7 / 10.


What is the financial health of JOHNSON & JOHNSON (JNJ.DE) stock?

The financial health rating of JOHNSON & JOHNSON (JNJ.DE) is 5 / 10.


Can you provide the expected EPS growth for JNJ stock?

The Earnings per Share (EPS) of JOHNSON & JOHNSON (JNJ.DE) is expected to grow by 7.91% in the next year.